Psoriasis Longitudinal Assessment and Registry (PSOLAR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00508547 |
Recruitment Status :
Active, not recruiting
First Posted : July 30, 2007
Last Update Posted : April 25, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Psoriasis |
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 15834 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 8 Years |
Official Title: | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics |
Actual Study Start Date : | June 21, 2007 |
Estimated Primary Completion Date : | December 31, 2029 |
Estimated Study Completion Date : | December 31, 2030 |
Group/Cohort |
---|
Guselkumab
Participants will receive guselkumab as prescribed by a physician according to standard of care for psoriasis.
|
Infliximab
Participants will receive infliximab as prescribed by a physician according to standard of care for psoriasis.
|
Ustekinumab
Participants will receive ustekinumab as prescribed by a physician according to standard of care for psoriasis.
|
Biological Therapies
Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
|
Conventional Systemic Agents
Participants will receive conventional systemic agents as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
|
IL-17 Inhibitor
Participants will receive an IL-17 inhibitor as prescribed by a physician according to standard of care for psoriasis.
|
- Adverse Events and Serious Adverse Events [ Time Frame: Up to 8 years of follow up for each patient ]An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; suspected transmission of any infectious agent via medicinal product; any important medical events. All adverse events, including those of special interest, such as malignancies;TB;opportunistic infections;depression;hypersensitivity reactions; autoimmune disease; neurologic or demyelinating events; congestive heart failure; gastrointestinal events; demyelinating disease, hepatotoxicity; hematologic events; unexpected reaction to a vaccine;cerebrovascular accident; transient ischemic attack; confirmed myocardial infarction; acquired immunodeficiency syndrome will be documented.
- Evaluation of disease features: Physicians global assessment of disease activity (PGA) Score [ Time Frame: At baseline and every 6 months through up to 8 years ]
- Evaluation of Disease Features: Body surface area [ Time Frame: At baseline and every 6 months through up to 8 years ]
- Evaluation of Disease Features: Psoriasis Area and Severity Index (PASI) Score [ Time Frame: At baseline and every 6 months through up to 8 years ]
- Dermatology Life Quality Index (DLQI) Score [ Time Frame: At baseline and every 6 months through up to 8 years ]
- EuroQOL quality of life assessment [ Time Frame: At baseline and every 6 months through up to 8 years ]
- Hospital Anxiety and Depression Scale (HADS) Score [ Time Frame: At baseline and every 6 months up to Month 18 and then every year up to 8 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Have a diagnosis of psoriasis
- Incident or prevalent users of Tremfya or an IL-17 inhibitor (eg, secukinumab, ixekizumab, brodalumab, bimekizumab) at the time of their enrollment. Incident users are defined as those participants starting treatment within 30 days before or after the enrollment visit and prevalent users are defined as those who are on treatment greater than 30 days prior to the enrollment visit
- Ability to understand and sign an informed consent form
- Are willing to participate in regular follow-up visits
Exclusion Criteria:
- Refuse to consent or are unwilling to respond to requests for long term information within the required time frame
- Are participating or have already planned to participate in a clinical trial with non-marketed investigational agents or are participating in a Janssen-sponsored clinical trial with marketed agents
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00508547
Study Director: | Janssen Scientific Affairs, LLC Clinical Trial | Janssen Scientific Affairs, LLC |
Responsible Party: | Janssen Scientific Affairs, LLC |
ClinicalTrials.gov Identifier: | NCT00508547 |
Other Study ID Numbers: |
CR013225 PSOLAR ( Other Identifier: Janssen Scientific Affairs, LLC ) |
First Posted: | July 30, 2007 Key Record Dates |
Last Update Posted: | April 25, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Device Product: | No |
psoriasis psoriatic arthritis skin disease infliximab ustekinumab guselkumab etanercept |
adalimumab secukinumab ixekizumab brodalumab systemic therapy observational registry |
Psoriasis Skin Diseases, Papulosquamous Skin Diseases |